Salman F Rahman Quits Beximco Boards, Paving Way For Group Restructuring

🏛 Salman F Rahman, former private industry and investment adviser to ousted prime minister Sheikh Hasina, has agreed to resign from the boards of Beximco Group companies, a move expected to break a nearly two-year regulatory and legal deadlock and clear the way for long-delayed board meetings. The development marks a significant milestone in the restructuring of one of Bangladesh's largest conglomerates, which had been effectively paralysed since the political transition of August 2024.

📊 Salman, who has been in jail since August 2024 and is facing multiple criminal charges, agreed to step down following discussions with the government, according to sources familiar with the matter. The group's three listed companies — Beximco Ltd, Beximco Pharmaceuticals PLC, and Shinepukur Ceramics PLC — have separately informed the Bangladesh Securities and Exchange Commission (BSEC) of Salman's intention to resign and sought regulatory approval to reconstitute their boards, according to letters obtained by The Business Standard.

💰 Beximco Pharma Board Restructuring Proposal

Under the proposed structure, the Beximco Pharma board would comprise four directors nominated by foreign shareholders, one director from local financial institution IFIC Bank, three sponsor directors, two independent directors in line with the Corporate Governance Code and a newly appointed managing director. However, the proposed restructuring faces a regulatory hurdle because Salman's exit would reduce the combined shareholding of the sponsor group below the required 30% threshold.

A person familiar with the matter said Beximco Group and related sponsor shareholders, including IFIC Bank, currently hold around 30% of Beximco Pharma, with Salman alone holding about 2%. His departure would therefore reduce the sponsor group's combined holding to roughly 28%, below the regulatory requirement. The BSEC has suggested bringing foreign shareholders onto the board or adding another shareholder to the sponsor group to address the shortfall, according to sources.

• 🏛 Listed companies affected: Beximco Ltd, Beximco Pharmaceuticals PLC, Shinepukur Ceramics PLC
• 💰 Salman's shareholding in Beximco Pharma: ~2%
• 💰 Sponsor group combined holding: ~30% → ~28% post-exit
• 📊 Regulatory threshold: 30% minimum sponsor holding
• 📈 DSEX gain on announcement day: +93 points
• 🌏 Beximco Pharma also listed on: London Stock Exchange AIM
• 📜 Proposed board: 4 foreign + 1 IFIC + 3 sponsor + 2 independent + 1 MD

🤝 Foreign Shareholder Reluctance

The company has already approached its foreign shareholders, but they have shown reluctance to join the board, a source said. Discussions are continuing to find a solution. "The immediate challenge is to maintain the required sponsor holding if the existing foreign shareholders decline to join the board," the source said, adding that bringing another shareholder into the sponsor group could be one possible solution.

BSEC Chairman Masud Khan told The Business Standard that the commission would accept the board reconstruction proposals after the regulatory issue concerning the combined shareholding of Beximco Pharma's sponsors is resolved. He also said it was clear that Salman F Rahman would no longer remain on the boards of Beximco Group companies. For Beximco companies without foreign shareholders, the restructuring is expected to be relatively straightforward, with independent and other proposed directors to be appointed subject to regulatory approval, according to sources.

📜 Legal Proceedings And Court Understanding

A source also said an understanding had been reached regarding the existing court proceedings, under which the relevant writ petition or stay order would be withdrawn, clearing the way for board restructuring. The withdrawal of court proceedings — which had been blocking board meetings and AGMs for nearly two years — would remove the legal barrier that has prevented the companies from conducting routine corporate governance activities including financial reporting, dividend declarations and strategic decision-making.

Beximco Pharmaceuticals, which is also listed on the Alternative Investment Market (AIM) of the London Stock Exchange, said the appointment of new directors would have to comply with applicable AIM rules. The dual-listing on the London Stock Exchange adds a layer of regulatory complexity — any board restructuring must satisfy both BSEC requirements and AIM governance standards, which include independent director provisions and shareholder approval processes that may differ from Bangladeshi regulations.

📈 Market Reaction: DSEX Gains 93 Points

The development has also eased uncertainty surrounding Beximco Group in the stock market. Shares of all three listed companies gained on September 15 as the DSEX rose 93 points after falling for five consecutive trading sessions. The market's positive reaction — breaking a five-session losing streak — reflects investor relief that the governance deadlock at one of Bangladesh's largest listed conglomerates is finally being resolved. The Beximco companies collectively represent a significant share of DSE market capitalisation, and their governance paralysis had been weighing on broader market sentiment.

🌏 Strategic Implications For Bangladesh's Corporate Sector

For Bangladesh's broader corporate sector, the Beximco restructuring carries strategic significance. The conglomerate — spanning pharmaceuticals, textiles, ceramics, real estate and financial services — is one of Bangladesh's most internationally recognised corporate groups, with Beximco Pharma's products exported to over 100 countries. The governance restructuring, if successfully executed, would restore the company's ability to hold board meetings, approve financial statements, declare dividends and make strategic investment decisions — activities that have been effectively frozen since August 2024.

The restructuring also signals the interim government's approach to corporate accountability — pursuing legal action against individuals (Salman F Rahman faces multiple criminal charges) while allowing the underlying businesses to continue operations under restructured governance. This distinction between individual accountability and corporate continuity is critical for maintaining investor confidence in Bangladesh's corporate sector during the broader political transition.

The coming months will reveal whether the Beximco board restructuring can be completed without further legal complications, and whether the reconstituted boards can restore the operational momentum that has been lost during the governance paralysis. For Beximco Pharma's international operations — including exports to regulated markets in the EU, US and Middle East — the restoration of normal board governance is essential for maintaining regulatory compliance with international pharmaceutical manufacturing standards.